2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial by Kellokumpu-Lehtinen, Pirkko-Liisa, Prof, Harmenberg, Ulrika, MD, Joensuu, Timo, MD, McDermott, Ray, MD, Hervonen, Petteri, MD, Ginman, Claes, MD, Luukkaa, Marjaana, MD, Nyandoto, Paul, MD, Hemminki, Akseli, Prof, Nilsson, Sten, Prof, McCaffrey, John, Prof, Asola, Raija, MD, Turpeenniemi-Hujanen, Taina, Prof, Laestadius, Fredrik, MD, Tasmuth, Tiina, MD, Sandberg, Katinka, MD, Keane, Maccon, MD, Lehtinen, Ilari, BSc, Luukkaala, Tiina, MSc, Joensuu, Heikki, Prof

Get full text